Assembly Biosciences, Inc. Revenue from Contract with Customer, Including Assessed Tax
Assembly Biosciences, Inc. (ASMB) reported Revenue from Contract with Customer, Including Assessed Tax of $13.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-13
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $13.37M, a 38.94% increase year-over-year.
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $8.21M, a 12.80% decline year-over-year.
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $10.79M, a 57.62% increase year-over-year.
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $9.63M, a 12.81% increase year-over-year.
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $28.52M, a 298.16% increase from fiscal 2023.
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $7.16M.
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Assembly Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $6.25M, a 92.09% decline from fiscal 2020.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 0 month | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.37M 10-Q · filed 2026-08-13 | $21.59M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $8.21M 10-Q · filed 2026-05-07 | ||||
| 2025-09-30 | $10.79M 10-Q · filed 2025-11-10 | $20.41M derived: sum of 2 quarters · filed 2026-08-13 | $29.83M 10-Q · filed 2025-11-10 | $37.19M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $9.63M 10-Q · filed 2026-08-13 | $19.05M 10-Q · filed 2026-08-13 | $26.40M derived: sum of 3 quarters · filed 2026-08-13 | $33.25M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $9.42M 10-Q · filed 2026-05-07 | $16.78M derived: sum of 2 quarters · filed 2026-05-07 | $23.62M derived: sum of 3 quarters · filed 2026-05-07 | $32.15M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $14.20M derived: sum of 2 quarters · filed 2025-11-10 | $22.73M derived: sum of 3 quarters · filed 2025-11-10 | $28.52M 10-K · filed 2025-03-20 | |
| 2024-09-30 | $6.84M 10-Q · filed 2025-11-10 | $15.38M derived: sum of 2 quarters · filed 2025-11-10 | $21.16M 10-Q · filed 2025-11-10 | $28.33M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $8.53M 10-Q · filed 2025-08-06 | $14.32M 10-Q · filed 2025-08-06 | $21.48M derived: sum of 3 quarters · filed 2025-08-06 | $21.48M derived: sum of 4 quarters · filed 2025-08-06 | |
| 2024-03-31 | $5.79M 10-Q · filed 2025-05-08 | $12.95M derived: sum of 2 quarters · filed 2025-05-08 | $12.95M derived: sum of 3 quarters · filed 2025-05-08 | $12.95M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $7.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $7.16M derived: sum of 2 quarters · filed 2025-03-20 | $7.16M derived: sum of 3 quarters · filed 2025-03-20 | $7.16M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $6.25M derived: sum of 2 quarters · filed 2023-03-22 | $6.25M 10-K · filed 2023-03-22 | ||
| 2021-09-30 | $6.25M 10-Q · filed 2022-11-08 | $6.25M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $1.04M 10-K · filed 2021-02-25 | $35.65M derived: sum of 2 quarters · filed 2021-11-04 | $75.02M derived: sum of 3 quarters · filed 2021-11-04 | $79.11M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $34.61M 10-Q · filed 2021-11-04 | $73.99M derived: sum of 2 quarters · filed 2021-11-04 | $78.07M 10-Q · filed 2021-11-04 | $82.83M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $39.38M 10-Q · filed 2021-08-05 | $43.46M 10-Q · filed 2021-08-05 | $48.22M derived: sum of 3 quarters · filed 2021-08-05 | $52.45M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $4.08M 10-Q · filed 2021-05-06 | $8.85M derived: sum of 2 quarters · filed 2021-05-06 | $13.08M derived: sum of 3 quarters · filed 2021-05-06 | $16.16M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $4.77M 10-K · filed 2021-02-25 | $9.00M derived: sum of 2 quarters · filed 2021-02-25 | $12.08M derived: sum of 3 quarters · filed 2021-02-25 | $15.96M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $4.23M 10-K · filed 2021-02-25 | $7.31M derived: sum of 2 quarters · filed 2021-02-25 | $11.20M 10-Q · filed 2020-11-05 | $14.93M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $3.08M 10-K · filed 2021-02-25 | $6.97M 10-Q · filed 2020-08-05 | $10.70M derived: sum of 3 quarters · filed 2021-02-25 | $14.99M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $3.88M 10-K · filed 2021-02-25 | $7.62M derived: sum of 2 quarters · filed 2021-02-25 | $11.91M derived: sum of 3 quarters · filed 2021-02-25 | $15.12M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $3.73M 10-K · filed 2020-03-04 | $8.02M derived: sum of 2 quarters · filed 2020-03-04 | $11.24M derived: sum of 3 quarters · filed 2020-03-04 | $14.80M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $4.29M 10-K · filed 2020-03-04 | $7.50M derived: sum of 2 quarters · filed 2020-03-04 | $11.07M 10-Q · filed 2019-11-07 | $14.38M derived: sum of 4 quarters · filed 2020-03-04 | |
| 2018-06-30 | $3.22M 10-K · filed 2020-03-04 | $6.78M 10-Q · filed 2019-08-05 | $10.10M derived: sum of 3 quarters · filed 2020-03-04 | $12.76M derived: sum of 4 quarters · filed 2020-03-04 | |
| 2018-03-31 | $3.56M 10-K · filed 2020-03-04 | $6.88M derived: sum of 2 quarters · filed 2020-03-04 | $9.54M derived: sum of 3 quarters · filed 2020-03-04 | $11.90M derived: sum of 4 quarters · filed 2020-03-04 | |
| 2017-12-31 | $3.31M 10-K · filed 2019-02-28 | $5.97M derived: sum of 2 quarters · filed 2019-02-28 | $8.33M derived: sum of 3 quarters · filed 2019-02-28 | $9.02M 10-K · filed 2020-03-04 | |
| 2017-09-30 | $2.66M 10-K · filed 2019-02-28 | $5.02M derived: sum of 2 quarters · filed 2019-02-28 | $5.70M derived: sum of 3 quarters · filed 2019-02-28 | ||
| 2017-06-30 | $2.36M 10-K · filed 2019-02-28 | $3.04M derived: sum of 2 quarters · filed 2019-02-28 | |||
| 2017-03-31 | $684.00K 10-K · filed 2019-02-28 | ||||
| 2017-02-10 | $50.00M 10-Q · filed 2019-05-09 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |